Peptide library / FOXO4-DRI

FOXO4-DRI

FOXO4-DRI is an experimental cell-penetrating D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells.

Peptide & blend guide

The short version

Why people discuss it
Discussed for experimental senescent-cell clearance and longevity. Community interest does not establish benefit or a suitable treatment.
What it is
FOXO4-DRI is an experimental cell-penetrating D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells.
Biggest caution
Published findings are mechanistic, cell-based or animal research. They do not establish human senolytic efficacy, a lifespan benefit, dosing or clinical safety.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Sources report different amounts or schedules; the reference below is a named example, not a consensus.

Subcutaneous injection

Community reference · Not clinical guidance
Amount
3–5 mg
Frequency
Every other day
Duration / phase
3 total doses

Sparse experimental community pulse, not a validated regimen. A new source describes 0.25–0.5 mg daily for 8–16 weeks. Chronic dosing and a three-dose course must not be averaged or treated as equivalent. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library